Insulin Deintensification After Glucagon-Like Peptide-1 (GLP-1)-Based Therapy in Type 2 Diabetes: Evidence and a Practical Clinical Framework.
5 affiliations
- 1Endocrinology, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai, ARE.
- 2Internal Medicine, Detroit Medical Center/Wayne State University, Detroit, USA.
- 3Anatomy, University of Khartoum, Khartoum, SDN.
- 4Medical School, St. George's University, St. George's, GRD.
- 5Biomedical Sciences, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai, ARE.
Abstract
Glucagon-like peptide-1 (GLP-1)-based therapies have changed the management of insulin-treated type 2 diabetes by creating opportunities not only to improve glycemic control and body weight but also to reduce insulin exposure and simplify previously intensified treatment regimens. However, clinical guidance remains considerably clearer on when to initiate or intensify insulin than on how to safely reduce established insulin therapy after effective GLP-1-based treatment is introduced. This narrative clinical review examines evidence for insulin dose reduction, regimen simplification, prandial insulin withdrawal, and complete insulin withdrawal following initiation or intensification of GLP-1-based therapy in adults with type 2 diabetes. Randomized trials and real-world studies increasingly support simplification of complex insulin regimens, with the strongest direct evidence supporting reduction or withdrawal of prandial insulin in appropriately selected patients. Complete insulin withdrawal is achievable in some individuals but remains less extensively studied. A practical approach should distinguish basal from prandial insulin and integrate overall glycemic control with fasting and postprandial glucose patterns, hypoglycemia risk, current insulin requirements, and clinical features suggesting impaired endogenous insulin reserve. Continuous glucose monitoring or structured glucose monitoring can facilitate sequential adjustment as GLP-1-based therapy is titrated. Patients with marked hyperglycemia, previous ketosis or diabetic ketoacidosis, suspected autoimmune diabetes, or other evidence of clinically important insulin deficiency require greater caution. We propose an evidence-informed phenotype-based framework in which insulin components are progressively reassessed rather than routinely continued or withdrawn according to a fixed formula. The objective is not insulin independence itself, but identification of the least complex insulin regimen necessary to maintain safe, individualized glycemic control.
Related
- Rechallenge After Immune Checkpoint Inhibitors Myocarditis: Evidence and a Practical Framework
- Immune-checkpoint blockade and candidate predictive biomarkers in HIV-negative Kaposi sarcoma: current evidence and a practical research framework
- Measuring Functional Outcomes After Laser-Based Rehabilitation of Traumatic Scars and Burn Scar Contractures: A Structured Evidence Map and Practical Follow-Up Framework
- Choosing Between Anti-TROP2 ADCs in Advanced Breast Cancer Without Head-to-Head Evidence: A Practical Evidence-Informed Decision Framework Endorsed by the Polish Society of Clinical Oncology.
- Divergent ocular safety profiles of glucagon-like peptide-1 receptor agonists: a pharmacological heterogeneity framework
BibTeX
@article{elhassan2026insulin,
title = {{Insulin Deintensification After Glucagon-Like Peptide-1 (GLP-1)-Based Therapy in Type 2 Diabetes: Evidence and a Practical Clinical Framework.}},
author = {Ahmed Elhassan and Abu-Bekr Mohamed and Ahmed Mahgoub and Anaida Singh and Isra Ali},
journal = {Cureus},
year = {2026},
month = oct,
doi = {10.7759/cureus.117614},
url = {https://europepmc.org/article/MED/42999457},
note = {CC BY},
}
RIS
TY - JOUR
TI - Insulin Deintensification After Glucagon-Like Peptide-1 (GLP-1)-Based Therapy in Type 2 Diabetes: Evidence and a Practical Clinical Framework.
AU - Ahmed Elhassan
AU - Abu-Bekr Mohamed
AU - Ahmed Mahgoub
AU - Anaida Singh
AU - Isra Ali
PY - 2026
DA - 2026/10/07
JO - Cureus
DO - 10.7759/cureus.117614
UR - https://europepmc.org/article/MED/42999457
AB - Glucagon-like peptide-1 (GLP-1)-based therapies have changed the management of insulin-treated type 2 diabetes by creating opportunities not only to improve glycemic control and body weight but also to reduce insulin exposure and simplify previously intensified treatment regimens. However, clinical guidance remains considerably clearer on when to initiate or intensify insulin than on how to safely reduce established insulin therapy after effective GLP-1-based treatment is introduced. This narrative clinical review examines evidence for insulin dose reduction, regimen simplification, prandial insulin withdrawal, and complete insulin withdrawal following initiation or intensification of GLP-1-based therapy in adults with type 2 diabetes. Randomized trials and real-world studies increasingly support simplification of complex insulin regimens, with the strongest direct evidence supporting reduction or withdrawal of prandial insulin in appropriately selected patients. Complete insulin withdrawal is achievable in some individuals but remains less extensively studied. A practical approach should distinguish basal from prandial insulin and integrate overall glycemic control with fasting and postprandial glucose patterns, hypoglycemia risk, current insulin requirements, and clinical features suggesting impaired endogenous insulin reserve. Continuous glucose monitoring or structured glucose monitoring can facilitate sequential adjustment as GLP-1-based therapy is titrated. Patients with marked hyperglycemia, previous ketosis or diabetic ketoacidosis, suspected autoimmune diabetes, or other evidence of clinically important insulin deficiency require greater caution. We propose an evidence-informed phenotype-based framework in which insulin components are progressively reassessed rather than routinely continued or withdrawn according to a fixed formula. The objective is not insulin independence itself, but identification of the least complex insulin regimen necessary to maintain safe, individualized glycemic control.
SN - 2168-8184
ER -